Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib in Metastatic Colorectal Cancer
NCT03190616Phase 2Completed
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jul 2017
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in colorectal cancer (metastatic) (mCRC), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Progression-Free Survival. Started Jul 2017; status: completed.
02
Drugs
Rivoceranib
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT03190616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03190616.